Peel Hunt Reaffirms “Hold” Rating for Vectura Group PLC (VEC)
Peel Hunt restated their hold rating on shares of Vectura Group PLC (LON:VEC) in a research report sent to investors on Tuesday. Peel Hunt currently has a GBX 160 ($2.11) price objective on the stock.
A number of other equities research analysts have also commented on VEC. Shore Capital reiterated a buy rating on shares of Vectura Group PLC in a report on Wednesday, August 16th. Panmure Gordon reiterated a buy rating on shares of Vectura Group PLC in a report on Wednesday, August 30th. Numis Securities Ltd reiterated a buy rating and set a GBX 205 ($2.71) price target on shares of Vectura Group PLC in a report on Thursday, September 7th. Citigroup Inc. lowered their price target on shares of Vectura Group PLC from GBX 200 ($2.64) to GBX 180 ($2.38) and set a buy rating for the company in a report on Monday, September 18th. Finally, J P Morgan Chase & Co decreased their price objective on shares of Vectura Group PLC from GBX 210 ($2.77) to GBX 180 ($2.38) and set an overweight rating for the company in a report on Thursday, September 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of GBX 199.63 ($2.63).
In other Vectura Group PLC news, insider Andrew Derodra bought 82,000 shares of Vectura Group PLC stock in a transaction dated Thursday, September 7th. The shares were purchased at an average cost of GBX 90 ($1.19) per share, with a total value of £73,800 ($97,387.17). Also, insider Bruno Angelici bought 70,000 shares of Vectura Group PLC stock in a transaction dated Tuesday, September 12th. The stock was acquired at an average cost of GBX 99 ($1.31) per share, for a total transaction of £69,300 ($91,448.93). Insiders bought a total of 152,300 shares of company stock worth $14,339,904 over the last ninety days.
Vectura Group PLC Company Profile
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.